Expect decent upside for Ajanta Pharma over six-month horizon: Avinnash Gorakssakar, Miintdirect.com

In a chat with ET Now, Avinnash Gorakssakar, Head of Research, Miintdirect.com, shares his views on Ajanta Pharma:

ET Now: What is your call on Ajanta Pharma?

Avinnash Gorakssakar: If you look at the numbers, Ajanta Pharma has been showing strong numbers quarter on quarter almost 20-22 per cent growth in top line and bottom line has actually been fast.

Looking at the kind of price upside, incremental upside may be difficult. However, operationally from the company’s standpoint of view, I would say that at least earnings growth of 20-25 per cent for FY'14 and FY'15 looks possible.

In that sense clearly there is a good, decent upside possible clearly over a 6 to 12 month kind of horizon.